Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) Advertising (25)
- (-) Fees and payments (4)
- Committees and advisory bodies (388)
- Scheduling (national classification system) (171)
- Safety monitoring and information (27)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Type of content
Search
29 result(s) found, displaying 1 to 25
-
Corporate reportsThis Cost Recovery Implementation Statement (CRIS) 2025-2026 provides information on how we implement, and cost recover our regulatory activities.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsThis plan outlines our compliance and education priorities for 2024-2025.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsThis Cost Recovery Implementation Statement (CRIS) 2024-2025 provides information on how we implement, and cost recover our regulatory activities.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsThe strategy outlines the approach we will use to identify, engage with, and educate stakeholders about regulatory requirements and our compliance outcomes.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2022-23
-
Corporate reportsThis Cost Recovery Implementation Statement provides information on how the TGA, within the Department of Health, implements and cost recovers its regulatory activities.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsThis Cost Recovery Implementation Statement provides information on how the TGA, within the Department of Health, implements and cost recovers its regulatory activities
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2021-22
-
Meeting statementsA meeting of the Therapeutic Goods Advertising Consultative Committee was held on 17 August 2022.
-
Meeting statementsA meeting of the Therapeutic Goods Advertising Consultative Committee was held on 23 August 2021.
-
Meeting statementsA meeting of the Therapeutic Goods Advertising Consultative Committee was held on 31 March 2021
-
Corporate reportsThe Australian Government has accepted all 22 recommendations
-
Meeting statementsA meeting of the Therapeutic Goods Advertising Consultative Committee was held on 19 November 2020
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2019-20
-
Meeting statementsA meeting of the TGACC was held on 27 August 2020. A communique has been published.
-
Corporate reportsThe independent review is complete and the report now published.
-
Corporate reportsFinal Report on the impact of advertising reforms from the Expert Panel Review of Medicines and Medical Devices Regulation, and other initiatives
-
Meeting statementsCommunique from the meeting of the Therapeutic Goods Advertising Consultative Committee (TGACC).
-
Meeting statementsThe TGACC meeting was held on 20 Feb 2020, a communique has been published
-
Meeting statementsCommunique from the fourth meeting of the TGACC